Accessibility Menu
RetinalGenix Technologies logo

RetinalGenix Technologies

(OTC) RTGN

Current Price$4.00
Market Cap$75.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+33%
5 YearN/A
1 Year+10%
1 Month+0%
RetinalGenix Technologies last closing stock price
MetricPriceDate
Last closeUSD 4.002026-07-16
RetinalGenix Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 4.002026-07-01
1 month+0%USD 4.002026-06-05
3 month+25%USD 3.202026-04-17
Year to date+25%USD 3.202025-12-15
1 year+9.59%USD 3.652025-06-23
3 year-57.45%USD 9.402023-06-07
Since inception+33.33%USD 3.002022-02-24

RetinalGenix Technologies Financials at a Glance

Market Cap

$75.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.43M

EPS (TTM)

-$0.13

P/E Ratio

-30.53

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$4.00

Volume

10

Open

$4.00

Previous Close

$4.00

Daily Range

$4.00 - $4.00

52-Week Range

$3.20 - $4.01

Estimated Earnings Date

Mar 31, 2023

RTGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RetinalGenix Technologies

RetinalGenix develops devices to help doctors monitor and diagnose eye diseases. Its products let patients and physicians track eye health from home or clinics. These tools aim to make early detection of vision problems easier for people with diabetes or age-related conditions.

Gadgets for Your Gaze: Products and Services

  • RetinalGeniX Imaging System: Portable device for eye screening, especially for diabetes-related vision issues. (0% of revenue; no sales to date)
  • RetinalCam: In-home system for real-time eye monitoring and alerts to doctors. (0% of revenue; no sales to date)
  • DNA/GPS: Genetic mapping combined with eye imaging to help spot risks for diseases like Alzheimer’s. (0% of revenue; no sales to date)
  • RTG-2023 and RTG-2024: Drug candidates in development for age-related eye disease and Alzheimer’s-related dementia. (0% of revenue; no sales to date)
  • Clinical Initiatives: Research partnerships to test personalized eye treatments and expand physician participation. (0% of revenue; no sales to date)

Growth Spurts and Expansion Detours

  • Formed DNA/GPS Inc. subsidiary in 2023 to integrate genetic mapping with eye imaging.
  • Launched clinical research with Pearl IRB in 2024 for personalized eye disease evaluation.
  • Announced plans in 2025 to seek additional capital and consider a Nasdaq up-listing.
  • Expanded product pipeline in 2025 with new drug candidates for eye and neurological diseases.
  • Relies on Sanovas Ophthalmology for operational support and funding since inception.

What Makes RetinalGenix Stand Out

RetinalGenix combines eye imaging with genetic data to help spot disease risks early. Its devices work without dilating the pupil, making screenings more comfortable. The company operates with minimal overhead by using related-party resources and consultants.

Five Things You Need to Know

  • No revenue reported for Q2 2025 or any prior period.
  • Net loss was $649,418 in Q2 2025, a 2.1% improvement year-over-year.
  • Operating expenses decreased by 2.2% to $648,348 in Q2 2025.
  • Cash balance was $839 as of June 30, 2025, with $1.99 million in liabilities.

Bottom Line

RetinalGenix remains in early development, focusing on eye health technology and research. The company faces funding challenges but continues to expand its product pipeline and clinical partnerships.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Jerry Katzman, MD

Website

www.retinalgenix.com

Headquarters

Apollo Beach, FL 94954, US

RTGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

107.91%

Return on Capital

N/A

Return on Assets

-41891.90%

Earnings Yield

-3.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$75.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.84M

Volume

10

Avg. Volume

12.452

Financials (TTM)

Gross Profit

$24.00

Operating Income

-$570.71K

EBITDA

-$284.00

Operating Cash Flow

-$480.34K

Capital Expenditure

$0.00

Free Cash Flow

-$480.34K

Cash & ST Invst.

$180.00

Total Debt

$55.07K

RetinalGenix Technologies Performance Analysis

RetinalGenix Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
RetinalGenix Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
RetinalGenix Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.2564.6%
20232023-12-31USD -0.12-52.0%
20242024-12-31USD -0.2499.8%
20252025-12-31USD -0.13-45.7%
RetinalGenix Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-11.7%
Q32025-09-3015.3%
Q42025-12-31-9.7%
Q12026-03-314.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$642.00

+3.6%

Gross Margin

0.00%

N/A

Market Cap

$75.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$590.49K

-0.6%

EBITDA

-$588.59K

-0.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$180.00

-95.1%

Total Debt

$55.07K

-2.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.21K

-49.8%

Short Term Debt

$51.86K

+3.7%

Return on Assets

-418.92%

N/A

Return on Invested Capital

22.34%

N/A

Free Cash Flow

-$109.21K

+41.7%

Operating Cash Flow

-$109.21K

+41.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HITCHealthcare Integrated Technologies, Inc.
$0.30+0.00%
INNPFINNOCAN PHARMA Corp
$1.60-8.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
NUNu Holdings
$13.59-0.01%

Questions About RTGN

What is the current price of RetinalGenix Technologies?

RetinalGenix Technologies is trading at $4.00 per share.

What is the 52-week range for RetinalGenix Technologies?

Over the past 52 weeks, RetinalGenix Technologies has traded between $3.20 and $4.01.

How much debt does RetinalGenix Technologies have?

As of the most recent reporting period, RetinalGenix Technologies reported total debt of $55.07K.

How much cash does RetinalGenix Technologies have on hand?

RetinalGenix Technologies reported $180.00 in cash and cash equivalents in its most recent financial results.

What is RetinalGenix Technologies’s dividend yield?

RetinalGenix Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services